[Form 4] IGM Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

IGM Biosciences (IGMS) Form 4: CFO Misbah Tahir disclosed the sale of 8,741 common shares on 07/23/2025 at a weighted-average price of $1.2728 per share. The transaction was executed in multiple trades within a $1.27–$1.275 range and was explicitly undertaken to cover tax-withholding obligations associated with vesting restricted stock units (RSUs).

Following the sale, Tahir’s direct beneficial ownership stands at 170,061 shares. No derivative security transactions or additional acquisitions were reported. The filing represents a routine insider sale rather than a strategic disposition, and no other material events or financial metrics are included.

Positive

• CFO retains 170,061 shares, indicating continued alignment with shareholders.

Negative

• Reduction of 8,741 shares represents a decrease in insider ownership, albeit small.

Insights

Financial Analyst

TL;DR: Routine tax-related insider sale; negligible fundamental impact.

The Form 4 shows IGMS’s CFO sold 8,741 shares solely to satisfy RSU tax withholding, leaving a substantial holding of 170,061 shares. Given IGMS’s average daily volume, the dollar value (≈$11k) is immaterial and signals no change in strategic outlook. Investors typically view such sales as administrative; therefore, the disclosure is neutral for valuation or sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tahir Misbah

(Last) (First) (Middle)

C/O IGM BIOSCIENCES, INC.

3 EAST THIRD AVENUE, SUITE 200

(Street)

SAN MATEO CA 94401

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IGM Biosciences, Inc. [ IGMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2025		S(1)		8,741	D	$1.2728(2)	170,061	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. This transaction was executed in multiple trades at prices ranging from $1.27 to $1.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price.

	/s/ Misbah Tahir	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IGMS shares did the CFO sell?

The CFO sold 8,741 shares of common stock.

What was the sale price of the IGMS shares?

Shares were sold at a weighted-average price of $1.2728, within a $1.27–$1.275 range.

Why were the shares sold according to the Form 4?

The sale covered tax withholding obligations related to RSU vesting.

How many IGMS shares does the CFO now own?

After the transaction, the CFO beneficially owns 170,061 shares.

Did the filing report any derivative transactions?

No derivative securities were acquired or disposed of in this Form 4.